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tissue it does not liberate itself back to the 
plasma (8). It reaches quickly the place of 
infection and stays at its therapeutic levels 
for 6-8 months after the last pulse (1,3). 
The purpose of this study is to 
assess the effectiveness of orungal 
(itraconazole) pulse therapy in onychomy-
cosis of the hand. 
MATERIAL AND METHODS 
A female patient was treated with 
orungal (itraconazole) for onychomycosis 
of the hand. The regimen consisted of 
itraconazole given as "pulses", each last-
ing one week with 3 weeks between the 
second and the third pulse. The dosage of 
itraconazole was of200 mg twice per day 
(a total of400 mg daily). The therapeutic 
start was supplied by mycological exami-
nations - both microscopic and cultural 
(culture No 1241/31.V.1996).Thecaus-
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Routine treatment of of onychomycoses consists in single daily application of 
orungal (itraconazole)for 3-6 months. This study aims at assessing the effectiveness of 
orungal pulse therapy in onychomycoses of the hand. According to the new schedule, 
the drug is administered two times daily 2 capsules of 100 mg each for one week 
during three consecutive months. The effect of the pulse therapy in a female patient 
with onychomycosis of the hand after three months is excellent.The tolerability is good 
and there are no adverse effects at all. 
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The treatment of onychomycosis 
is rather difficult and quite a long process. 
The therapeutical schedules commonly 
used include the daily use of wide-spec-
trum antifungal preparations provided for 
several months. The patients treated in this 
way are monthly examined for unwanted 
side effects and for their biochemical data 
as well (4,5,9). 
Orungal (itraconazole) is atriazole 
derivative which is extremely effective 
against fungal infections (7). The most sig 
nificant mechanism of action is penetra-
tion in the nail by inserting into the nail 
matrix and diffusion through the nail leg 
(2,6,10). Itraconazole connects firmly with 
the nail keratin and after dispersing in the 
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ative organism was Trichophyton 
rubrum. 
Controls of the mycotic status 
were provided at the end of the third month 
as well as two years after the end of the 
pulse therapy. Routine biochemical blood 
analyses were monthly performed. No 
treatment with topical or other oral anti­
fungal agents had been administered for 
the whole period. 
RESULTS AND DISCUSSION 
The result of orungal (itraconazole) 
pulse therapy for onychomycosis of the 
hand was excellent. At the end of the third 
month a complete clinical and mycologi-
cal healing of the nail was observed. The 
patient responded well to itraconazole. 
No clinical and laboratory adverse effects 
were established at all. The therapeutic 
effect remains stable and persists 2 years 
after the end of pulse therapy. 
The pulse therapy with orungal 
(itraconazole) for onychomycosis pos­
sesses several advantages over the well-
known therapeutic schedules. Some of 
them are the following: 
1) short duration (one week) in a 
dosage of 200 mg twice a day; 
2) definite therapeutic result; 
3) lack of clinical and paraclinical 
adverse reactions; 
4) suitable schedules for use, and 
5) no need for concomitant topi­
cal antimycotic therapy. 
CONCLUSION 
A conclusion can be drawn that 
the pulse therapy wi th orungal 
(itraconazole) should be recommended as 
an effective, short lasting therapeutic 
schedule of choice for onychomycosis. 
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Пулс-терапия с орунгал (итраконазол) на онихомикоза 
П. Друмева, С. Рачева 
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Резюме: Стандартното лечение на онихомикозите се състои в еднократно дневно 
дозиране на орунгал (итраконазол) в продължение на 3 месеца. С това проучване се 
цели да се оцени ефективността на пулсовата терапия с орунгал при онихомикози на 
ръката. Съгласно новата схема, медикаментът се назначава два пъти дневно по две 
капсули по 100 mg за една седмица в продължение на 3 последователни месеца. След 
3 месеца ефектът от пулсовата терапия при болна с онихомикоза на ръката е отличен. 
Поносимостта е добра и няма никакви странични ефекти. 
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